Table 1.
Overview of studies reporting on the prevalence of immunosuppression in COVID‐19 patient samples
| Author | Title | Study design | Study quality (OCEBM) | Sample | Outcome of interest | Findings |
|---|---|---|---|---|---|---|
| Guan et al. 21 | Clinical characteristics of coronavirus disease 2019 in China | Retrospective cohort | 3 | 1099 patients with COVID‐19 disease | Number of immunosuppressed patients in cohort with COVID‐19 disease | 2/1099 COVID‐19 patients designated as immunosuppressed by study authors |
| Jin et al. 22 | Epidemiological, clinical and virological characteristics of 74 cases of coronavirus‐ infected disease 2019 (COVID‐19) with gastrointestinal symptoms | Retrospective cohort | 3 | 651 patients with COVID‐19 disease | Number of immunosuppressed patients in cohort with COVID‐19 disease | 1/651 COVID‐19 patients designated as immunosuppressed by study authors |
| Lian et al. 23 | Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID‐19) out of Wuhan | Retrospective cohort | 3 | 788 patients with COVID‐19 disease | Number of immunosuppressed patients in cohort with COVID‐19 disease | 1/788 COVID‐19 patients designated as immunosuppressed by study authors |
| Liang et al. 24 | Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China | Prospective cohort | 3 | 1590 patients with COVID‐19 disease | Number of immunosuppressed patients in cohort with COVID‐19 disease | 2/1590 COVID‐19 patients were designated as currently receiving chemotherapy. |
| Richardson et al. 25 | Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalised with COVID‐19 in the New York City area | Case series | 4 | 5700 patients with COVID‐19 disease | Number of immunosuppressed patients in cohort with COVID‐19 disease | 55/5700 COVID‐19 patients were designated as solid organ transplant recipients by study authors |
| Zhang et al. 26 | Clinical features and outcomes of 221 patients with COVID‐19 in Wuhan, China | Retrospective cohort | 3 | 221 patients with COVID‐19 disease | Number of immunosuppressed patients in cohort with COVID‐19 disease | 3/221 COVID‐19 patients were designated as recipients of immunosuppressant therapy by study authors |